
    
      This is a phase II , openlabel, randomized study in patients with confirmed diagnosis of
      resectable metastatic colorectal adenocarcinoma , who have not received prior chemotherapy
      for their metastatic disease. The study is designed to compare pathological responses
      observed after pre-operative chemotherapy bevacizumab with FOLFOX or FOLFIRI.
    
  